Entries by ZEO ScientifiX
Organicell Welcomes Harry Leider, MD, MBA as its New CEO
FORT LAUDERDALE, FL / ACCESSWIRE / June 21, 2023 / Organicell Regenerative Medicine, Inc. (OTCQB:OCEL), a clinical-stage biopharmaceutical company focused on the development of innovative biological regenerative therapeutics, is pleased to announce the appointment of Harry L. Leider, MD, MBA as its new Chief Executive Officer (CEO). Dr. Leider has a distinguished background as a highly innovative […]
Organicell Announces Matt Sinnreich as CEO
MIAMI, FL / ACCESSWIRE / July 26, 2022 / Organicell Regenerative Medicine, Inc. (OTCQB:OCEL), a clinical-stage biopharmaceutical company principally focusing on the development of innovative biological therapeutics in the extracellular vesicle space, announced today that the board of directors has appointed Matt Sinnreich as Chief Operating Officer and acting CEO. Sinnreich will replace Mr. Albert Mitrani, […]
Organicell Regenerative Medicine, Inc. Secures $4 Million in Funding for Clinical Trials and Agrees To Restructure Management
MIAMI, FL / ACCESSWIRE / July 20, 2022 / Organicell Regenerative Medicine, Inc. (OTCQB:OCEL), a clinical-stage biopharmaceutical company principally focusing on the development of innovative biological therapeutics for the treatment of degenerative diseases and the provision of related services, announced today that it has secured $4.0 million in funding to finance clinical trials of its products […]
Organicell’s “Advances of Exosome-Based Therapeutics in the Clinic” article featured on Bioinformant
“Organicell Regenerative Medicine is amongst the first groups of innovators to spearhead the use of naturally occurring extracellular vesicles as a next-generation therapeutic tool for inflammatory and chronic disease.” Learn more about Organicell’s “Advances of Exosome-Based Therapeutics in the Clinic” in our most recent published article on Bioinformant. Read the full article
Register Now for the 2nd Operationalize Expanded Access Programs Conference Happening February 15-17
Join Organicell along with leading Expanded Access Program thinkers sharing their expertise and knowledge towards bringing treatments to patients in need. Secure your spot by registering today: https://operationalize-eap.com/take-part/register/?utm_source=digital&utm_medium=social-post&utm_campaign=other-general-promotion&utm_content=linkedin/organicell-speaker/ev-23689
Register now for Advanced Therapies Week at the Miami Convention Center happening January 25-28.
Join Organicell along with leading developers, investors and solution providers looking to bring cell and gene therapies to patients. Secure your spot by registering today
Proof-of-Concept Trial of an Amniotic Fluid-Derived Extracellular Vesicle Biologic for Treating High Risk Patients with Mild-to-Moderate Acute COVID-19 Infection
Organicell’s latest research publication is now available to read in Biomaterials and Biosystems Journal, “Proof-of-Concept Trial of an Amniotic Fluid-Derived Extracellular Vesicle Biologic for Treating High Risk Patients with Mild-to-Moderate Acute COVID-19 Infection”.
We have dedicated this to our Primary Investigator who didn’t have the chance to see it published. Thank you Dr. Friedewald, your career has greatly impacted us and has left us inspired to continue your legacy.
Read the full publication here.
